Salarius Pharmaceuticals Inc SLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLRX is a good fit for your portfolio.
News
-
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
-
Salarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug Application
-
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood
Trading Information
- Previous Close Price
- $0.49
- Day Range
- $0.47–0.51
- 52-Week Range
- $0.43–2.31
- Bid/Ask
- $0.48 / $0.51
- Market Cap
- $2.42 Mil
- Volume/Avg
- 11,742 / 117,467
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.salariuspharma.com
Valuation
|
Metric
|
SLRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SLRX
Financial Strength
|
Metric
|
SLRX
|
|---|---|
Quick Ratio | 4.54 |
Current Ratio | 5.02 |
Interest Coverage | — |
Quick Ratio
SLRX
Profitability
|
Metric
|
SLRX
|
|---|---|
Return on Assets (Normalized) | −114.85% |
Return on Equity (Normalized) | −166.36% |
Return on Invested Capital (Normalized) | −167.78% |
Return on Assets
SLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dfhrxkkxd | Cfyfy | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ydpdrfnf | Hcvtm | $105.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ptjyrfqzc | Mvmyt | $105.3 Bil | |
MRNA
| Moderna Inc | Yfvlmzrfp | Vbgd | $46.7 Bil | |
ARGX
| argenx SE ADR | Hqknclw | Kvcl | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Fhsnrxds | Bcqfj | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fszyjnspk | Mvvwk | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fpgmfxp | Rfxsqj | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cjtpttdc | Pgfkffp | $12.6 Bil | |
INCY
| Incyte Corp | Tcwrynjm | Yjkgz | $12.0 Bil |